Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 5Antilymphocyte Serum 5fludarabine phosphate 4Flow Cytometry 4Tacrolimus 3Mycophenolic Acid 3Filgrastim 3Azacitidine 3Alemtuzumab 3thymoglobulin 2ruxolitinib 2abiraterone 2Stem Cell Transplantation 2Peripheral Blood Stem Cell Transplantation 2Microarray Analysis 2Methylprednisolone 2Methotrexate 2Immunologic Techniques 2Cyclosporine 2Busulfan 2Biopsy 2venetoclax 1trametinib 1sargramostim 1rucaparib 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1palbociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × JNJ-64264681 × Genitourinary × Clear all
NCT06788509 2026-06-05

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Janssen Research & Development, LLC

Phase 1 Enrolling by invitation
120 enrolled
GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡